
Current number of planned/ongoing studies using Olink = 69
As a provider of protein biomarker solutions for scientists seeking to re-shape future healthcare, Olink is taking the COVID-19 pandemic situation extremely seriously and is committed to support the crucial studies that will help better understand and eventually to better treat the disease.
See all applications related to COVID-19
Actions speak louder than words
Olink’s protein biomarker panels are already being used in a significant number of on-going and planned COVID-19 studies across North America, Europe and Asia, covering a range of objectives, including:
Prediction & prognosis:
- Understand basic biology and prognosis of disease severity
- Patient stratification by disease severity
- Longitudinal sampling (admission to recovery vs. death)
- Prediction of cytokine release storms in COVID-19 patients
- Prediction/prevention of ARDS (Acute Respiratory Distress Syndrome)
- Outcome predictions in CVD patients with COVID19
Therapies:
- Evaluation of re-purposed therapeutics
- Patients undergoing plasma-exchange
- Remdesivir
- IFNbeta-1
- IL-6
- Bradykinin pathways (repurposed rare disease drug)
- Chloroquine, Hydroxychloroquine,
- Ruxolitinib
- Camostat
- Azithromycin
- Lopinavir/Ritonavi.
- Effect of p38 inhibition on COVID-19 patients and cytokine storm
- Cardiac markers to determine use of ACE2 inhibitors
- Re-purposed immunotherapy for allergies
Comorbidities:
- Cancer
- Cardiovascular disease
- BMI
- Renal dysfunction
- Neurological effects
- Hematological malignancies
- Dermatological diseases
- HIV
You can read much more about how Olink is being used right now in COVID-19 research by downloading our informative and interactive infographic: